Compugen to Present at Upcoming Immuno-Oncology and Rheumatology Conferences
September 09 2015 - 7:00AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug
discovery company, today announced that aspects of its
immuno-oncology programs and its lead autoimmune program will be
presented at four upcoming scientific conferences.
In poster presentations at three upcoming oncology conferences,
Compugen’s scientists will present the Company’s unique predictive
discovery approach for novel drug targets with an emphasis on
selected novel immune checkpoint programs which are now being
advanced by the Company in the field of cancer immunotherapy.
Arthur Machlenkin, Ph.D., Head of Immuno-Oncology Research
at Compugen, will present at the CRI-CIMT-EATI-AACR - The Inaugural
International Cancer Immunotherapy Conference: Translating
Science into Survival, to be held between September 16-19, 2015, in
New York.
Ofer Levy, Ph.D., Principal Scientist at Compugen, will present
at the 7th International Conference on Tumor
Microenvironment, to be held between October 11-15, 2015, in
Tel Aviv, Israel.
Galit Rotman, Ph.D., Chief Scientist, Therapeutics at Compugen,
will present at the Society for Immunotherapy of Cancer’s (SITC’s)
30th Anniversary Annual Meeting & Associated Programs, to be
held between November 4-8, 2015, in National Harbor, MD.
The Company’s lead program for autoimmune diseases, CGEN-15001,
a therapeutic fusion protein based on a Compugen-discovered immune
checkpoint protein candidate, will be the subject of an oral
presentation by Iris Hecht, Ph.D., Principal Scientist at Compugen,
at the American College of Rheumatology Annual Meeting to take
place between November 6-11, 2015, in San Francisco. Dr. Hecht’s
talk, on Sunday, November 8, titled "CGEN-15001, a Novel B7-like
Protein, Controls Inflammation in a Translational Rheumatoid
Arthritis (RA) Assay and Induces Treg Driven Long-Term Remission in
an Autoimmune Disease Model," will be given as part of the
Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and
Angiogenesis session and will include recent data for CGEN-15001
obtained using immune cells of rheumatoid arthritis patients.
About Compugen
Compugen is a leading drug discovery company utilizing its
broadly applicable predictive discovery infrastructure to identify
novel drug targets and develop first-in-class biologics. The
Company’s current pipeline focus is on immune checkpoint target
candidates discovered by the Company, potentially providing the
basis for a next wave of therapeutics for cancer immunotherapy.
Compugen’s business model is based on selectively entering into
collaborations for its novel targets and drug product candidates at
various stages of research and development under revenue-sharing
agreements. The Company is headquartered in Tel Aviv, Israel, with
R&D facilities in Tel Aviv and South San Francisco. At the US
facilities, monoclonal antibody therapeutic candidates are
discovered and developed against the Company’s novel target
candidates. For additional information, please visit Compugen's
corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as “will,” “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks
include: that Compugen’s business model is substantially dependent
on entering into collaboration agreements with third parties and
may not be successful in generating revenues, and that the
development and commercialization of therapeutic products includes
many inherent risks, including failure to progress to clinic or, if
progressed, failure to receive regulatory approval. These and other
factors are more fully discussed in the "Risk Factors" section of
Compugen’s most recent Annual Report on Form 20-F as filed with the
Securities and Exchange Commission as well as other documents that
may be subsequently filed by Compugen from time to time with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150909005823/en/
Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media
Liaisontsipih@cgen.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024